Nutrition and Dietetics articles for Lilly, United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 10

Article ‘Count’ for Nutrition and Dietetics.

Journal Count Share
1 0.50
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity 0.50
1 0.46
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF The SUMMIT Trial 0.46
4 1.83
Data-driven prioritization of high-risk individuals for weight loss interventions 0.19
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial 0.40
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency 0.67
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial 0.58
3 1.68
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial 0.54
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial 0.44
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial 0.70
1 0.46
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment 0.46

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.